Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
To evaluate the clinical efficacy and safety of hypofractionation radiotherapy combined with
sintilimab，GM-CSF and Fruquintinib in Patients With MSS Metastatic Colorectal Carcinoma
(mCRC)
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Xiamen University